Pulse Biosciences (NASDAQ: PLSE) announced the publication of first-in-human clinical results using its Nanosecond Pulsed Field Ablation (nsPFA) technology for benign thyroid nodules, with data appearing in the peer-reviewed Journal Thyroid.
The study, conducted in Naples, Italy, tested the CellFX nsPFA Percutaneous Electrode System under ultrasound guidance. Results showed nodules shrank by an average of 86% after one year, with some cases achieving up to 93% reduction. Symptom relief and measurable volume reduction were evident within two weeks, and no fibrosis or scarring was observed on follow-up imaging—underscoring the technology’s precision and safety profile.
Unlike traditional thermal ablation, nsPFA uses a nonthermal mechanism, sparing critical structures such as nerves and blood vessels. Clinicians involved in the trial highlighted that volume reductions occurred more rapidly than with conventional approaches like radiofrequency ablation, which typically require six months to show similar results.
For investors, the publication validates nsPFA’s potential as a disruptive alternative to surgery and thermal ablation, offering a minimally invasive outpatient treatment with faster recovery and a cleaner safety profile. The peer-reviewed data adds clinical credibility and positions Pulse Biosciences for potential regulatory advancement and commercial adoption in a large and underserved market.
The post Pulse Biosciences Publishes First-in-Human Data on Thyroid Nodule Treatment appeared first on PRISM MarketView.
